沙库巴曲缬沙坦用于射血分数降低的心力衰竭：心源性休克。
Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock.
作者信息
Rawal H A, Kocheril A G
机构信息
Internal Medicine, University of Illinois at Urbana-Champaign, 611 West Park St., Urbana, IL 61801, USA.
Department of Cardiovascular Diseases and Clinical Electrophysiology, Christie Clinic, 1400 West Park St., Urbana, IL 61801, USA.
出版信息
Case Rep Cardiol. 2018 May 15;2018:8231576. doi: 10.1155/2018/8231576. eCollection 2018.
Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was started on this new medication. On sacubitril/valsartan, he developed cardiogenic shock. This led us to reevaluate the use and risks of this medication in the class IV heart failure population.
沙库巴曲缬沙坦是一种复方药物，被描述为用于治疗心力衰竭的新型双重作用血管紧张素受体脑啡肽酶抑制剂（ARNi）。我们报告了一例纽约心脏病协会（NYHA）心功能IV级收缩性心力衰竭患者的病例，该患者对所有其他类别的心力衰竭药物均无反应，开始使用这种新药治疗。使用沙库巴曲缬沙坦后，他发生了心源性休克。这促使我们重新评估该药物在IV级心力衰竭人群中的使用和风险。
Zotero 插件